公开(公告)号：US20220324970A1

公开(公告)日：2022-10-13

申请号：US17630718

申请日：2020-07-31

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Bharathikumar Vellalore MARUTHACHALAM ,  Adam ZWOLAK ,  Brian GEIST ,  Xiefan LIN-SCHMIDT ,  Sathyadevi VENKATARAMANI ,  Sanjaya SINGH

IPC: C07K16/28 ,  A61K47/68 ,  A61K47/65

Abstract: A method is described for delivering a single domain antibody or a therapeutic molecule from an apical surface of a polymeric immunoglobulin receptor (pIgR)-expressing cell to a basolateral surface of the pIgR-expressing cell comprising contacting the pIgR-expressing cell with the single domain antibody or the therapeutic molecule, wherein the single domain antibody binds to pIgR, and the therapeutic molecule comprises an agent and the single domain antibody. A method is also described for transporting such a therapeutic molecule to systemic circulation or lamina propria or gastrointestinal tract of a subject comprising administering the therapeutic molecule to the subject via oral delivery, buccal delivery, nasal delivery or inhalation delivery.

公开(公告)号：US20220356266A1

公开(公告)日：2022-11-10

申请号：US17233021

申请日：2021-04-16

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Adam ZWOLAK ,  Jason HO ,  Natasa OBERMAJER ,  Michael DIEM ,  Sanjaya SINGH ,  Sathyadevi VENKATARAMANI ,  Theresa MCDEVITT ,  Fei SHEN

IPC: C07K16/30 ,  C07K16/28

Abstract: A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.

公开(公告)号：US20250011454A1

公开(公告)日：2025-01-09

申请号：US18703264

申请日：2022-10-19

Applicant: Janssen Biotech, Inc.

Inventor： Adam ZWOLAK ,  Jason HO ,  James TESTA, Jr. ,  Michael Riis HANSEN ,  Xiefan LIN-SCHMIDT ,  Ian WHITE ,  Sanjaya SINGH

IPC: C07K16/28 ,  C07K16/30

Abstract: Provided herein, in certain aspects, is a binding molecule comprising an antigen binding domain and an Fc region; wherein the antigen binding domain is monovalent and the Fc region comprises K248E and T437R mutations (RE mutations), wherein amino acid residue numbering is according to the EU numbering system; wherein the binding molecule has increased capability of hexamerization on a cell surface, and/or increased capability of engaging C1q.

公开(公告)号：US20220033522A1

公开(公告)日：2022-02-03

申请号：US17391744

申请日：2021-08-02

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Adam ZWOLAK ,  Ian WHITE ,  Ninkka TAMOT ,  Paul B. HARVILLA ,  Rajitha DODDAREDDY ,  Sanjaya SINGH ,  Martin Jack BORROK III

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10

Abstract: Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.

公开(公告)号：US20240025992A1

公开(公告)日：2024-01-25

申请号：US18249807

申请日：2021-10-21

Applicant: Janssen Biotech, Inc.

Inventor： Danlin YANG ,  Sanjaya SINGH ,  Scott R. BRODEUR ,  Jill M. CARTON ,  Rajkumar GANESAN ,  Jennifer HERTZOG ,  Theresa MCDEVITT ,  Kristen M. PICHA ,  Ryan M. SMITH ,  Adam ZWOLAK ,  Sathyadevi VENKATARAMANI ,  Gordon D. POWERS

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K49/00

CPC classification number: C07K16/28 ,  A61K47/6849 ,  C07K16/2809 ,  C07K2319/30 ,  A61K49/0002 ,  C07K2317/622 ,  C07K2317/31 ,  A61P35/00

Abstract: Antibodies and antigen binding regions that bind delta-like protein 3 (DLL3) are described. Multispecific antigen-binding constructs, such as bispecific antibodies, containing the antigen-binding regions that bind to DLL3 are also described. The application also describes methods of treatment or detection using the anti-DLL3 antibodies, antigen-binding fragments or multispecific antigen-binding constructs thereof, and related molecules, compositions and methods.

公开(公告)号：US20230019640A1

公开(公告)日：2023-01-19

申请号：US17630706

申请日：2020-07-31

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Bharathikumar Vellalore MARUTHACHALAM ,  Adam ZWOLAK ,  Brian GEIST ,  Xiefan LIN-SCHMIDT ,  Sathyadevi VENKATARAMANI ,  Sanjaya SINGH

IPC: C07K16/28 ,  A61K47/68 ,  A61P11/00

Abstract: VHH domains that bind to p1gR are described. The VHH domain may compete with IgA binding to p1gR, or alternatively, the VHH domain may compete with IgA binding to p1gR. The VHH domains may be coupled to therapeutic agents so as to facilitate delivery of the therapeutic agent to the mucosal layer via p1gR-mediated transcytosis. The therapeutic agent can be a small molecule, large molecule, or even an antibody.

公开(公告)号：US20220056104A1

公开(公告)日：2022-02-24

申请号：US17405872

申请日：2021-08-18

Applicant: JANSSEN BIOTECH, INC.

Inventor： Adam ZWOLAK ,  Szeman CHAN ,  Rajkumar GANESAN

IPC: C07K14/705 ,  C07K14/765 ,  A61P37/04

Abstract: Described herein are compositions and kits that comprise an engineered TL1A ligand that displays high stability, minimal binding to decoy receptor DcR3 while retaining functional activity via binding to its cell surface receptor, DR3, and the ability to activate T cells in vitro and in vivo. Methods of making an engineered TL1A ligand and methods of treating a disease or disorder in a subject by administering an engineered TL1A ligand are also provided.